COLL Stock Recent News

Collegium Pharmaceutical (COLL) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

Collegium (COLL) reports financial guidance for full-year 2024 and business updates. Shares of the company rise on the same.

Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

STOUGHTON, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that management will participate in the following investor conferences:

Today, we revisit Collegium Pharmaceutical, Inc., which has seen a 30% increase in its stock price since our last look at it in June 2022. Collegium Pharmaceutical has done a good job integrating Belbuca into its product portfolio, paying down debt and recently accelerating a stock buyback program. We take a look at the company's future prospects in the paragraphs below.

STOUGHTON, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2023 financial results after the market closes on Tuesday, November 7, 2023. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Collegium Pharmaceutical is a specialty pharmaceutical company focused on developing innovative treatments for chronic pain with abuse-deterrent technology. The company's financials show solid sales momentum, decreased operating expenses, improved profitability, and increased cash position. Collegium's product lineup includes Xtampza ER, Nucynta IR, and candidates in clinical development, all utilizing the company's DETERx technology.

Collegium Pharmaceutical presents attractive value for investors with a forward earnings multiple of 4.5x and a 30% return on capital deployed. Q2 earnings indicate potential for momentum and a target price of $33/share in my view. The stock has shown technical breakouts and market data supports a bullish outlook.

Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.